PMID: 6967055Mar 15, 1980Paper

Collaboration between specific anti-tumor immunity and chemotherapeutic agents

International Journal of Cancer. Journal International Du Cancer
Y YamamuraT A Mahvi

Abstract

Treatment of DBA/2J mice bearing a T1699 syngeneic mammary adenocarcinoma (Ts) with a single intraperitoneal (i.p.) injection of 100 ug melphalan produced complete tumor regression in about 65% of the animals treated; however, tumors recurred in about 85% of these regressors after 15-25 days' remission. The drug regimen was ineffective against Ts tumors growing in immunosuppressed or immunodeficient animals. Stimulation of immunologically intact Ts tumor-bearers with bacterial lipopolysaccharide (LPS) or with phytohemagglutinin (PHA) 3 days prior to melphalan therapy, on the other hand, produced not only higher rates of tumor regression but also significant increases in the number of permanent cures. A tumor induced by T1699 subline TR2 was resistant to the same regimen, although Ts and TR2 cells were equally susceptible to the cytotoxic and growth-inhibiting activities of the drug in vitro. In contrast, the combination of specifically armed monocytes and melphalan in vitro produced enhanced killing of Ts cells but not of TR2 cells. Analysis of the collaborative cytotoxicity between immune effector cells and melphalan indicated that exposure of tumor cells to killer cells increased the drug susceptibility of the tumor cells, bu...Continue Reading

References

May 15, 1977·International Journal of Cancer. Journal International Du Cancer·Y YamamuraJ S Haskill
May 1, 1977·International Journal of Radiation Oncology, Biology, Physics·J P ConcannonJ Conway
Jun 1, 1978·Journal of the National Cancer Institute·J H KornF L Ritter
Mar 1, 1978·Cancer Treatment Reviews·D M Green, N Jaffe
Mar 1, 1978·International Journal of Radiation Oncology, Biology, Physics·J P ConcannonE Markopoulos
Jun 1, 1978·Journal of the National Cancer Institute·J H KornF L Ritter
May 15, 1977·International Journal of Cancer. Journal International Du Cancer·Y Yamamura
Jun 15, 1976·International Journal of Cancer. Journal International Du Cancer·L A RadovJ H Korn
Nov 15, 1975·International Journal of Cancer. Journal International Du Cancer·J S HaskillL Radov
Dec 15, 1974·International Journal of Cancer. Journal International Du Cancer·G SteeleJ Ankerst
Oct 1, 1974·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G MathéC Bourut
Jul 1, 1973·British Journal of Cancer·J C Campbell
Feb 1, 1974·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J L Amiel, M Berardet
Mar 15, 1973·International Journal of Cancer. Journal International Du Cancer·M Moore, D E Williams
Mar 15, 1974·International Journal of Cancer. Journal International Du Cancer·R L StolfiD S Martin

❮ Previous
Next ❯

Citations

Oct 15, 1981·International Journal of Cancer. Journal International Du Cancer·A M IorioE Bonmassar
Jan 15, 1984·International Journal of Cancer. Journal International Du Cancer·Y YamamuraJ W Proctor
Aug 31, 2012·Oncoimmunology·Lorenzo GalluzziGuido Kroemer
Jul 23, 1982·Science·M G Hanna, M E Key

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.